News Trump's DOJ reschedules medicinal marijuana, increasing acce... The US Justice Department has issued an order moving medical marijuana to Schedule III, removing some barriers to access for patients and researchers.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
News Trump, Pfizer announce MFN deal; Lilly, others to come At the White House today, President Trump and Pfizer CEO Albert Bourla announced the first of many deals to secure MFN drug prices for US consumers.
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Market Access Four months, 157 Executive Orders: Inside the science of Tru... When Donald Trump returned to the White House in January 2025, the question wasn't whether his administration would change the direction of US health policy – it was how quickly, how deeply
Patients Op-ed: Pharma must show courage, leadership on public health Pharma companies can't claim to care about global patient wellbeing unless they stand up to Trump's public health cuts.
News AZ will invest £300m in UK, says PM Keir Starmer AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.